Boehringer Ingelheim and Isis combine cell adhesion programs in $100 mil. agreement.
Executive Summary
BOEHRINGER INGELHEIM AND ISIS COMBINE CELL ADHESION PROGRAMS WORTH $100 MIL. to the antisense firm in a letter of intent agreement. The collaboration, announced March 1, would combine Boehringer Ingelheim and Isis' clinical and research programs aimed at developing cell-adhesion targeted drugs. The cell adhesion alliance is subject to a definitive agreement that the companies say is expected to close in the second quarter. B-I's financial advisor for the transaction is Vector Securities.